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harmacological developments in the 20th cen-
tury have produced a wide range of drugs that have
greatly improved the treatment of many serious diseases.
In psychopharmacology, the discoveries of antipsychotic,
tranquillizing, or antidepressant agents, such as selective
serotonin reuptake inhibitors (SSRIs), were milestones
in the treatment of mental illness. However, compared
with the general pharmacological progress, the psy-
chopharmacological development, whilst noteworthy,
has been somewhat less spectacular. Despite heavy
investments in mental health-related research,
1 there
have been few important discoveries since the 1950s,
when a number of psychopharmacological agents were
discovered that are still in use. For example, clozapine
was synthesized over 50 years ago but continues to be
described as the “most effective antipsychotic drug” for
the treatment of schizophrenia,
2 and is recommended in
the UK National Institute of Health and Clinical
Excellence (NICE) 2009 update to its schizophrenia
guidance.
3
Traditionally, the drugs developed have been “one size
fits all,” ie, standardized drugs targeting symptoms or
syndromes that can be shared by various diseases, rather
than being disease-specific, let alone patient-specific.
Even though health care is by definition personalized in
the sense that the patient’s needs broadly determine the
nature of recommended treatment, eg, type and dosage
of medication, traditional medication leaves little room
for individual variations in responses to treatment,
notably through the randomized double-blind procedure
used in clinical trials that is incompatible with individu-
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Pharmacogenomic developments hold promise for per-
sonalized medicine in psychiatry with adjusted thera-
peutic doses, predictable responses, reduced adverse
drug reactions, early diagnosis, and personal health plan-
ning. The prospects are exciting, but at the same time,
these new techniques stand faced with important scien-
tific, ethical, legal, and social challenges that need to be
met in order for the scientific advances to be responsibly
applied. This review discusses the ethical balance
between challenge and opportunity of personalized
medicine in psychiatry under the aspects of adequacy,
cost:benefit ratio, and therapeutic equity. It is argued
that the promising nature of these therapeutic possibil-
ities makes it all the more important to avoid exagger-
ating the expectations, and that a sophisticated social
infrastructure needs to be developed in order to ensure
the realistic and responsible application of personalized
medicine in psychiatry.
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:427-434.
427 Copyright © 2009 LLS SAS.  All rights reserved www.dialogues-cns.org
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 427alized assessment. This can be regarded both as a
strength, because the structure of the trials ensures that
known or unknown confounding factors are evenly dis-
tributed between the treatment groups, thus yielding
accurate results; or as a weakness because individuality
is not taken into account. For better or for worse, drugs
are not individually developed; they do not target the
individual biological system.
However, human individuals are, biologically as well as
socially, highly varied, and a common medical problem
is that people with similar symptoms, or the same illness,
may react quite differently to a prescribed drug. Even
if available data justify the prescription of a given drug,
the effects of this drug can vary extensively between dis-
tinct individuals. Whereas one individual may be greatly
helped by the drug, another may be more or less non-
responsive to it; and whilst one patient will suffer severe
side effects, another will not. From the point of view of
the patient, it is clearly of interest to know if one
belongs to the group (normally, the majority) that is
helped by the drug, or to the minority that is not,
whether one will suffer side effects, and, if so, of what
type and degree. For society, adverse drug responses
(ADRs) are a major medical and economic problem.
ADRs cause thousands of deaths and serious injuries
yearly, and have even been suggested to constitute
between the fourth and the sixth leading cause of death
in the US, which would rank ADRs ahead of pneumo-
nia and diabetes.
4Thus the concern felt by many people
regarding what side effects they are likely to experience
is very valid: even a brief glance at the most common or
important side effects may be rather alarming. The side
effects of psychopharmacological drugs can be very seri-
ous, including loss of muscular coordination, slowing of
reactions, addiction, and psychiatric conditions other
than the one targeted by the drug (eg, depression or
anxiety).
The prescription of drugs that may have serious side
effects is not a satisfactory area for a trial-and-error
strategy, by which one might prescribe or take a drug
with reasonable hope for good results but without know-
ing in advance what will happen. Even if side-effect pro-
files are admittedly dynamic, the risk:benefit ratio pos-
itive, serious side effects statistically uncommon, and
prescription of the drug in agreement with the gold stan-
dard of psychiatric treatment in a given context, a physi-
cian or a patient might still hesitate to prescribe or take
it, and wish to know if her/his individual biological struc-
ture is compatible with the drug or not. Will the drug
help? If so, at what price? What can be done to optimize
its therapeutic effects?
Until recently, there were no options available other
than a probability calculus based on data collected from
previous and ongoing experience. There were scant pos-
sibilities to determine in advance how the patient as an
individual would react to the drug. Unsatisfactory, per-
haps, but unavoidable: he or she had to take it to find
out, a fact that we have “generally accepted with a cer-
tain fatalism.”
5
The door to making such informed individual predic-
tions was opened when, in the mid 1950s, the link
between genetic makeup and drug metabolism was iden-
tified
6; ie, when it was discovered that the causes for indi-
vidual variation in drug response could be genetic.
7
More precisely, when the extent to which the causes of
diverse drug response could be genetic was realized, for
the genetic determination of the capacity of an organism
to respond to its environment has long been accepted in
biology,
8 including the implication of enzymes in the
detoxification of foreign substances.
9 In addition to non-
genetic and environmental causes and lifestyle factors,
eg, age, gender, family support, good diet, care in fol-
lowing prescriptions, etc, variations in DNA sequence
among individuals (genetic polymorphisms) were also
found to be involved in the response to drug therapies.
10
Accordingly, knowledge of the individual genome
became strongly relevant to drug prescription.
11
Increasing knowledge of the human genome has given
rise to the development of genomic medicine, genetic
testing, and also helped in diagnosing some unusual dis-
orders; still, the impact of genetics in medicine during the
20th century was relatively modest.
12The recent devel-
opment of new technologies for genetic testing has pro-
moted new studies in how drugs and genes interact with
potentials for much larger impact.
13 Pharmacogenetics (a
term coined in the 1950s
14) is the study of individual vari-
ations in drug response due to heredity. It can be distin-
guished from pharmacogenomics, a broader term denot-
ing all genes in the genome that may influence drug
response, but the terms are often used interchangeably.
15
There is considerable hope that new and more effective
treatments for numerous mental disorders can result if
drugs are developed that specifically target the responsi-
ble genes, eg, schizophrenia susceptibility genes.
16
If drug prescription can be personalized, ie, tailored to
suit the individual’s genetic makeup,
17 this holds promise
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medication with adjusted therapeutic doses, predictable
drug responses, reduced ADRs, and personal health
planning.
18 It should be noted that personalization and
individualization, depending on how the concepts are
interpreted, need not mean the same thing, and that they
are in this context a matter of degree. Here, “personal-
ized medication” can logically, but not realistically, be
interpreted as medication developed to suit the singular
individual. The realistic interpretation is that personal-
ized medication is “relatively individualized” in the sense
of drugs having a more limited group specificity than the
earlier “one size fits all” drugs.
Other suggested benefits are considerable time and cost
reductions in the pharmaceutical development,
19 and the
possibility of pharmacogenomics to simplify the clinical
trial process.
20The prospects are exciting, but at the same
time, these new techniques stand faced with important
ethical, legal, and social challenges that need to be met
in order for the scientific advances to be responsibly
applied. Below, the ethical balance between challenges
and opportunities of personalized medicine in psychia-
try from the points of view of adequacy, cost, and thera-
peutic equity, are reviewed.
Sound promotion versus hype
The sequencing of the human genome and the tentative
identification of genes' underlying susceptibility to men-
tal disorders suggest the possibility of developing novel
and more effective treatments for these disorders.
Increased knowledge of the pathways for the patho-
physiology of major mental illnesses can, it is hoped, lead
to major therapeutic breakthroughs, the assumption
being that understanding of the pathophysiological basis
of these illnesses will enable the development of tar-
geted drugs and new curative therapies.
21
On the basis of genetic knowledge about patients’ drug
metabolic status, several studies recommend adjustment
of therapeutic doses of antidepressants
22 or antipsy-
chotics
23 in relation to CYP2D6, CYP2C9, and CYP2C19
phenotypes. The implementation of these techniques in
clinical practice—which is the ultimate goal of pharma-
cogenomics research in this field—can significantly
improve psychiatric treatment in terms of adequate dos-
ing, reduced side effects, averted toxic events, and
improved treatment adherence and efficacy.
24 On the
other hand, looking at the development in pharmacoge-
nomics from the perspective of earlier hopes for gene
transfer-based therapies, there is a non-negligible risk
that scientists and their funding agencies, as well as the
pharmaceutical industry, play up or hype the possibili-
ties.
25
The primary concern is with scientific adequacy. Are the
scientific underpinnings of the pharmacogenomic
promises sound? Do the players sufficiently acknowl-
edge the scientific uncertainties that are connected to
pharmacogenomics research; for example, the complex
interactions between genes/brain/environment that
underlie the development of mental disorders? In order
to appreciate the significance of genetic explanations of
complex and heterogeneous disorders, such as schizo-
phrenia, eg, in terms of the genetic susceptibility for its
development, it is necessary also to understand the role
of epigenetic factors (heritable genomic functions that
are not contained in the DNA sequence code) and fac-
tors related to the psychosocial environment.
26 Likewise,
in order to properly assess genotype-specific psy-
chopharmacological products, complex epigenetic inter-
actions must be taken into account. The human brain is
fundamentally a biosocial structure, and mental health
throughout life depends on social as well as biological
conditions.
27The brain develops within a “genetic enve-
lope,” but the evolution of its architecture is subject to
important social impact, notably, through the gigantic
weight of the cultural imprints epigenetically stored in
our brains.
28 The formation of synapses is both prenatal
and postnatal; it is far from complete at birth. The post-
natal development of the human brain lasts considerably
longer than in any other animal. The most intense devel-
opment occurs during the first 2 years, but it continues
to puberty and after, and the highest executive functions
that are determined by the frontal lobe are not fully
mature until the age of around 20.
29The environment is
important for this process to be efficient. If neural net-
works are not active, they vanish
30: “Use it or lose it!,” as
the mantra goes. In the absence of adequate stimulation,
the cerebral network suffers irreversible injury,
31 and
serious mental disorders might develop.
Genetic, epigenetic, neurophysiologic, and psychosocial
explanations of mental illness are complementary; they
do not stand opposed in modern psychiatry. However, a
correct understanding of the interactions between these
distinct perspectives in the complex causal structures
underlying mental disorders and their curative therapies
is hard to achieve. This is not a new challenge, specific to
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ized in this new context. More effective treatments for
mental disorders can indeed result if drugs are devel-
oped that specifically target the genes responsible. Yet
the role of genes in causing mental disorders is
extremely complex, as is the connection between geno-
type and phenotype in drug metabolism.
32 It is, for exam-
ple, not possible to base high-probability predictions of
drug responses on single genetic variations.
33Whilst the
possible contributions of molecular biology to psy-
chopharmacological drug discovery are important,
34 they
must not be overemphasized or oversimplified.
35
It is important and legitimate for science, health care,
and the pharmaceutical industry to try to promote new
ideas and new types of drugs; however, if the expecta-
tions are exaggerated this may undermine public trust
36
and reduce financial support in the longer perspective.
This is what happened to gene therapy: “When legiti-
mate promotion became hype, followed by very public
failures of clinical trials, venture capital and government
sponsors withdrew from the field. The result was that sci-
entific research suffered, and the public and other stake-
holders were left holding an empty bag of promises.”
37
It has been claimed that enthusiasts within the academic
and business fields of pharmacogenomics are guilty of
too much speculation and unsubstantiated claims.
38
Skeptics point not only to the scientific uncertainty con-
cerning the promises held out, but also to exaggerations
in the promised reductions in ADRs,
39 and to the
cost:benefit ratio suggested. There are signs of hype
being created, when, in 2006, the pharmaceutical indus-
try predicted that by 2010, “the discovery and develop-
ment process will take half as long as it does now, and
costs per drug will fall to a quarter of the current aver-
age.”
40 It is not impossible that their prediction will come
true in due course, but we are not there yet, and at the
time of writing that prediction seems, at least timewise,
overly optimistic.
The sociological analyses of these expectations have
focused on how key actors communicate visions about
future prospects of the new technology.
41 These key
actors represent different interests, eg, industry, govern-
ment, health care providers, or patient groups. Their
visions are seen as coconstructions where each actor is
actively helping to shape the trajectory of an emerging
promising technology.
42 Even bioethics is suggested as a
helpmate, actively recruited by pharmaceutical compa-
nies and the biotech scientific community in order to
serve as a ”political brooker.”
43A basic message in these
sociological analyses is that industry, the medical pro-
fession, and patient groups are coresponsible for pro-
ducing hype, and they call for a more social-science
based analysis of the science behind pharmacogenomics
to obtain a more realistic view of what can actually be
achieved, to unravel the interests pressing for early
implementation, and to deconstruct the hype.
44 In that
context, it must not be ignored that social scientists, eg,
ethicists, themselves may feed on the hype and be guilty
of producing it. In other words, the methods of social sci-
ence should be used without, however, excluding social
science as an object for scrutiny.
Cost versus benefit
The first-generation antipsychotic drug clozapine is still
recommended in the UK National Institute of Health
and Clinical Excellence (NICE) 2009 update to its schiz-
ophrenia guidance, but in a 2002 Press Release, NICE
“recommends newer antipsychotic drugs as one of the
first-line options for schizophrenia.”
45 The choice
between newer and first-generation drugs depends in
part on the relative benefits of the drugs and their side
effects, and in part on the health care budget. 
An important reason to recommend newer rather than
first-generation psychopharmacological drugs is that the
latter tend to have more severe side effects (eg, heart
disorders such as myocarditis and cardiomyopathy, the
blood disorder agranulocytosis, or tardive dyskinesia, a
movement disorder that is potentially irreversible). On
the other hand, the newer drugs tend to be more expen-
sive, sometimes considerably so. Often the incremental
efficacy is not very spectacular, but the tolerance is
improved at a cost that is unbearable for the health care
system. Hence, there is a clear health care budget issue
involved in the selection of drugs.
Developing new drugs is an increasingly costly proce-
dure.
46The development phase can take many years and
is very expensive. The testing phase needed to deter-
mine, eg, if the drug is effective, safe, and by what
method and dosage it is best delivered to the organ sys-
tem, can also take many years and is likewise very
expensive. More and more requirements are raised by
the regulatory agencies, and, of potential new medicines,
few will ever reach the stage of marketing and selling—
a phase that can cost even more than the preceding two
combined. These factors jointly make pharmaceutical
Clinical research
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maceutical companies do what they can to recoup their
outlays.
In recent years, the balance of power has shifted, and the
market has become more difficult for the pharmaceuti-
cal companies, due to, for example, expiring patents,
attrition in the pipelines, and the fact that governments,
insurance companies, and patients increasingly dictate
what kind of drugs they want, and how much they are
willing to pay for them. This means that it is not just the
drug makers who define the threshold of innovation, but
also the health care demanders. In this situation, where
the pharmaceutical industry has seen its value dwindle
compared with the glory days of the 1990s, the contri-
butions of molecular biology to drug discovery hold
promise of increased profit for the pharmaceutical com-
panies.
Concerning the cost:benefit ratio of pharmacogenomic
drug development, there are profoundly different visions
of the future. According to the optimistic vision, a better
understanding of how different diseases function both at
a molecular level and as part of a biological system
might enable the industry to define diseases far more
precisely, and to develop drugs that are targeted towards
specific disease types, rather than making one-size-fits-
all drugs focusing on symptoms shared by a range of dif-
ferent diseases.
47 Many new drugs will then be based on
biology rather than chemistry because biologic entities
are typically more predictable and less toxic than chem-
ical entities. In the aim to “get the right drug into the
right patient,”
48 human research subjects will be geno-
typed in clinical trials to find out likely drug responses,
a development also predicted importantly to reduce the
time and cost of making new drugs.
If that prediction is correct, then the cost of drug devel-
opment might pose less of a problem in the case of tar-
geted medication than in the case of one-size-fits-all
drugs. Pharmacogenomic developments could thus lead
to better health care without increasing the customer
prices, and perhaps even reducing them. This can then
be a win-win situation, where patients receive better
health care whilst industry boosts its revenues.
Skeptics (amongst whom we also find some sectors of
the pharmaceutical industry)
49 recommend a more cau-
tious view, arguing that the niche products that pharma-
cogenomics would produce risk segmenting the market,
increasing the development costs, and reducing profits.
The research, argue the skeptics, will take longer than
predicted to produce clinical applications, and that the
alleged cost-saving will therefore not be provided.
50
Of course, the cost:benefit ratio of new therapeutic cures
may be difficult to determine in advance; yet the argu-
ment of pharmacogenomic cost-efficiency can be ques-
tioned on a general basis. The market for a genotype-
specific drug is perforce smaller than that of the one type
fits all variety. Even if the development process becomes
more efficient, the development of highly specialized
drugs that target small rather than large populations can
also lead to very expensive drugs. The need for pharma-
ceutical companies to recoup their investments is an eco-
nomic reality that can clash with the interests of health
care, and it is not self-evident that the latter’s concerns
will outweigh the former.
Therapeutic winners versus losers
The screening of participants in clinical trials by geno-
type raises several ethical problems. Such stratification
might lead to the unfair representation of specific groups
in these trials, as well as a reduction in the number of
subjects included, which could affect the study’s exter-
nal validity and clinical applicability.
51 Even with more
cost- and time-efficient clinical trials, if researchers can
recruit only people with a certain genotype for the test-
ing of a specific drug,
52 there is a risk connected to the
fact that the prospective drug is tested only on a small
and genetically homogenous group. Side effects might
go undetected in the case of people who do not have this
genotype, which means that a drug could be marketed
with less premarketing exposure and less information
about adverse effects. This may not be a problem if only
patients with the tested genotype use it, but if (eg,
through prescription error, or nonprescribed uses) some-
one with a different genotype takes it, the knowledge of
possible additional side effects for these people is want-
ing. This is different from drug errors with the random-
ized tested traditional drugs. In the case of the latter, if
a person unjustifiably takes a nonprescribed drug, or if
a psychiatrist erroneously prescribes a drug, eg, an anti-
depressant, the possible risks and side effects are rea-
sonably well foreseeable, and can probably be treated if
the person seeks medical assistance. If the same person
erroneously takes a genotype-specific drug, there is no
tested knowledge about what might happen.
This is not an argument against the development of geno-
type-specific drugs, but an argument for the development
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 431of a social infrastructure to handle their distribution. The
problem highlights many challenges involved in inte-
grating pharmacogenomic drugs into psychiatric care, eg,
the need for simple and accessible pharmacogenetic tests
with clinical guidelines that allow psychiatrists and health
care personnel to use these tests adequately, and to pre-
scribe or recommend pharmacogenetic drugs,
53 as well as
the need for effective measures to prevent nonprescribed
use. The genetic information obtained must also be
legally safeguarded to protect privacy and confidential-
ity,
54 and calls for caution have been made to “regulate
the use of genetic tests.”
55
A further problem remains, from the point of view of the
patient, that is connected to the costs involved in tar-
geted drug development. This concerns the fact that
some people may belong to less profitable patient
groups.
In order to regain the investment in a drug that is tar-
geted towards a small population, the price must be
higher than if the drug were able to be distributed to a
large population. This economic principle poses a prob-
lem for so-called “orphan diseases,” ie, medical condi-
tions that are either too rare, or that touch populations
too poor for drug development in that area to be prof-
itable. Less profitable patient groups stand a smaller
chance of having remedies developed than profitable
patient groups with diseases that are also prevalent in
developed countries. To remedy the situation, public
policies in many countries fund or facilitate research
aiming to produce “orphan drugs” specifically targeted
to treat these rare conditions, or these diseases that pri-
marily haunt poor populations. Now pharmacogenomics
introduces a new way of belonging to a less profitable
patient group. To the traditional criteria of having a rare
disease, or being burdened by poverty, we may now add
having a rare genotype.
When new pharmacogenomic drugs are developed they
need to be tested in specific patient groups targeted by
specific drugs. However, it might be difficult to find a suf-
ficient number of patients for a trial of rare variants of
individual biomarker profiles.
56 It can also be expensive
to develop a new drug for such small groups. Patients
with less profitable genotypes are therefore at risk of
becoming “therapeutic orphans,” and governments may
need to extend their orphan drug policies to remedy this
additional form of inequity.
57
If pharmacogenomic drug development enables preci-
sion in the inclusion of patients that can be helped by a
drug, it ipso facto entails the equally targeted exclusion
of those that cannot. The limit between pharmacological
inclusions versus exclusions can in some cases be a ques-
tion of race, or ethnicity. For example, drugs to treat high
blood pressure, or hypertension, have different effects
on black versus Caucasian populations, as the high num-
ber of clinical trials investigating this listed on the US
National Institute of Health’s Web site on clinical trials
illustrates.
58 The concept “race” is scientifically contro-
versial; some claim that “race is biologically meaning-
less,”
59 whereas others argue that this depends on how
the concept is defined.
60 In pharmacology, it seems well
established that different ethnic groups, at least, respond
in different manners to drugs, which is one reason why
the International Conference on Harmonization (ICH)
was created to harmonize the technical requirements for
registration of pharmaceuticals for human use in the
three main regions: Europe, the US, and Asia. Japan has
insisted that due to their ethnic pharmacological speci-
ficity, phase 1 studies must always also be done in Asian
populations.
61
If therapeutic (in)equity can be connected to race, or
ethnicity, this is something that the social assessment of
pharmacogenomic drug development needs to take into
account. As the problem of orphan drugs and diseases
illustrates, pharmaceutical companies have no obligation
to develop drugs in an equitable manner, eg, with racial
or ethnic nonbias. If a racial or ethnic group is very small,
for example, the cost:benefit ratio for developing drugs
to treat that group may not be economically rewarding.
This is a further form of possible discrimination that gov-
ernments may need to deal with in their health care and
health research policies in order to ensure the protection
of genetic or ethnic minorities.
Conclusion
Personalized medicine in psychiatry, eg, in the form of
tailored antidepressant or antipsychotic treatment, has
already made important progress, notably in terms of
adjusted therapeutic doses, and predictable drug
responses or drug-induced side effects. Although promis-
ing, these opportunities also give rise to numerous sci-
entific, ethical, legal, and social challenges. An adequate
assessment of personalized medicine in psychiatry must
within all these perspectives be based both on analyses
of the science behind pharmacogenomics research to get
a realistic view of what can actually be achieved, and on
Clinical research
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rounding this research. Justified hopes must not be
inflated to become hypes of exaggerated promises that
would serve no legitimate purpose. Signs of hype, for
instance in the form of pressures for rash implementa-
tion, should be forestalled and a realistic view presented.
Realistic cost:benefit analyses are needed to produce
reasonable health care budgets; pharmacogenetic tests
must be developed together with guidelines for their use,
so that the new techniques can be responsibly imple-
mented in clinical practice; public policies on orphan dis-
eases and drugs may need to be extended to avoid cre-
ating a new group of “genetic orphans”; whilst legal
regulations are needed to ensure that the genetic infor-
mation obtained is safely protected from misuse, and
that genetic or ethnic minorities are protected from dis-
crimination.
The ethical considerations that have here been consid-
ered in terms of adequacy, cost, and therapeutic equity
raise no objections to the development of personalized
medicine per se in this domain. Rather, they point to the
necessity of developing a social infrastructure with ade-
quate guidelines to ensure the responsible implementa-
tion of these promising new techniques.  ❏
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La medicina personalizada en psiquiatría:
oportunidades y desafíos éticos
Los progresos farmacogenómicos generan espe-
ranzas para la medicina personalizada dentro de la
psiquiatría en cuanto a ajuste de dosis terapéuticas,
respuestas predecibles, reducción de las reacciones
adversas a los fármacos, diagnóstico precoz y pro-
gramas personales de salud. Las posibilidades son
apasionantes, pero al mismo tiempo estas nuevas
técnicas se enfrentan con importantes desafíos cien-
tíficos, éticos, legales y sociales, los que requieren
estar de acuerdo con los avances científicos para
que ellas se puedan aplicar responsablemente. Esta
revisión discute el balance ético entre los desafíos y
oportunidades de la medicina personalizada en psi-
quiatría en relación con aspectos de adecuación,
relación costo beneficio y equidad terapéutica. Se
argumenta que el carácter prometedor de estas
alternativas terapéuticas hace aun más importante
evitar la exageración de las expectativas y que se
necesita desarrollar una sofisticada infraestructura
social para asegurar la aplicación realista y respon-
sable de la medicina personalizada en psiquiatría. 
Médecine personnalisée en psychiatrie :
opportunités et défis éthiques 
Les développements de la pharmacogénomique ont
tenu leurs promesses pour la médecine personnali-
sée en psychiatrie en permettant d’ajuster les doses
thérapeutiques, de prévoir les réponses, de dimi-
nuer les effets indésirables, d'établir des diagnos-
tics précoces et des calendriers personnels de santé.
Les perspectives sont prometteuses mais en même
temps, ces nouvelles techniques doivent faire face
à des défis scientifiques, éthiques, légaux et sociaux
importants  afin de permettre aux avancées scien-
tifiques de s’appliquer de manière responsable.
L’équilibre éthique entre défi et opportunité de la
médecine personnalisée en psychiatrie fait l’objet
ici d’une discussion au sujet de sa pertinence, de son
rapport coût/bénéfice, et de son équité thérapeu-
tique. La nature prometteuse de ces possibilités thé-
rapeutiques prend le pas sur le risque d’attentes
exagérées ; la mise en application réaliste et res-
ponsable de la médecine personnalisée en psychia-
trie demande de développer une infrastructure
sociale sophistiquée.
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